IL33 and chronic rhinosinusitis with nasal polyps: Nonetheless, new biological strategies target epithelial‐derived alarmins such as IL‐33 (etokimab, itepekimab) and thymic stromal lymphopoietin (tezepelumab) in CRSwNP [46].